Celgene's AML drug clears late-stage test

Celgene is gearing up for regulatory submissions, after a pivotal acute myeloid leukemia (AML) study showed its drug helped patients live longer.

The drugmaker — which is in the process of being swallowed by Bristol-Myers Squibb $BMY — tested its experimental drug, CC-486, in newly-diagnosed patients with AML who fully or partially benefited from chemotherapy.